跳至主要内容
临床试验/CTRI/2021/11/038192
CTRI/2021/11/038192已完成不适用

A Multicenter Retrospective Study tounderstand the clinicalcharacteristics, treatment pathway and resource utilizationfor patients with chronic lymphocytic leukemia.

AstraZeneca Pharma India Ltd10 个研究点 分布在 1 个国家目标入组 1,250 人开始时间: 2021年3月12日最近更新:

试验速览

阶段
不适用
状态
已完成
入组人数
1,250
试验地点
10
主要终点
(1) Recording patient characteristics.

研究概览

简要总结

This is a retrospective, observational, registry-based study including patients with a diagnosis of CLL and started treatment (1st line, 2nd line, or Subsequent lines of treatment) data for a given patient will be collected during a one-time summary of medical records and will include at least one year of the patient’s data.

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • Primary diagnosis of Chronic Lymphocytic Leukemia (CLL)
  • Initiated CLL treatment (including 1st line 2nd line or Subsequent lines of treatment) within the period between 01 June 2016 and 12 months before data collection For GCC pilot cohort patients: treatment naive CLL patients diagnosed between 01 June 2016, and 12 months before data collection
  • Available medical records at the participating site reflecting at least 12 months of follow-up after starting on treatment (except in the case of the participant death within one year following treatment initiation)
  • Provision of informed consent by the patient or next of kin/legal representative (for deceased patients at study entry unless a waiver was granted) according to local regulations
  • Adult male or female ≥18 years old at the time of diagnosis or according to the age of majority as defined by local regulations).

排除标准

  • Failure to meet one or more of the inclusion criteria.
  • Any diagnosis of B cell malignancies other than CLL.
  • Current or prior use of acalabrutinib treatment.
  • Currently previously receiving treatment in an interventional clinical trial at the time of entry into this study for indications CLL.

结局指标

主要结局

(1) Recording patient characteristics.

时间窗: one-time

(2) Recording disease characteristics.

时间窗: one-time

次要结局

  • (1) Recording the treatment patterns. (2) Recording the treatment-related outcomes.(one-time)

研究者

申办方类型
Pharmaceutical industry-Indian

研究点 (10)

Loading locations...

相似试验